http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110638846-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2021-6432 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2021-6439 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-6428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-6486 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277 |
| filingDate | 2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110638846-B |
| titleOfInvention | Application of RNase L inhibitor |
| abstract | The invention discloses application of an RNase L inhibitor, which comprises application of specific compounds in preparation of RNase L inhibitors, oncolytic virus anti-tumor synergists and anti-tumor products and pharmaceutical compositions, wherein the specific compounds have targeted specificity on RNase L. The prepared RNase L inhibitor can effectively inhibit the activity of RNase L, prevent oncolytic virus from being degraded, ensure that the oncolytic virus can be successfully replicated in host tumor cells and kill the tumor cells, and effectively improve the anti-tumor effect of the oncolytic virus. On the basis, the RNase L inhibitor and the specific oncolytic virus can be compounded into an anti-tumor product, so that the normal exertion of the effect of killing tumor cells by the oncolytic virus is ensured. |
| priorityDate | 2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.